Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019
Veru Inc. (VERU)
Last veru inc. earnings: 2/12 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
verupharma.com/investors
Company Research
Source: GlobeNewswire
MIAMI, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that four abstracts have been accepted for poster presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium to be held February 14-16, 2019, at the Moscone West Building in San Francisco, California. Three of the presentations will be for VERU-111, the Company’s proprietary, next generation, first-in-class selective oral tubulin inhibitor for the treatment of advanced prostate cancer which is enrolling in a Phase1b/2 clinical study, and the fourth presentation will be for zuclomiphene citrate (VERU-944), a proprietary oral estrogen receptor agonist drug for the treatment of hot flashes caused by androgen deprivation therapy (ADT) for men with advanced prostate cancer which is currently enrolling in a Phase 2 clinical trial. Additional information on the meeting can be found on the ASCO Genitourin
Show less
Read more
Impact Snapshot
Event Time:
VERU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERU alerts
High impacting Veru Inc. news events
Weekly update
A roundup of the hottest topics
VERU
News
- What Makes Veru (VERU) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock, down previously from $7.00.MarketBeat
- Veru Announces Date of 2024 Annual Meeting of Shareholders [Yahoo! Finance]Yahoo! Finance
- Veru Announces Date of 2024 Annual Meeting of ShareholdersGlobeNewswire
- Veru Inc. (NASDAQ: VERU) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock.MarketBeat
VERU
Earnings
- 8/10/23 - Beat
VERU
Sec Filings
- 4/1/24 - Form DEFA14A
- 4/1/24 - Form 10-Q
- 4/1/24 - Form 10-K/A
- VERU's page on the SEC website